Skip to content
ContentLora

    Tip: press / anywhere to search.

    Explainer

    Cancer immunotherapy in 2026: a crash course

    Cancer immunotherapy is treatment that helps the immune system fight cancer.[1] Since the first checkpoint inhibitor was approved in 2011, it has grown into a family that includes engineered T cells, bispecific antibodies and personalised vaccines.[2][3] In 2026 the frontier is solid tumours, with a first phase 3 win for a personalised mRNA vaccine and the first CAR-T approval for a solid tumour, in China.[4][5]

    Editor reviewedStrict sourcingUpdated Cancer immunotherapyHealth and medicineLife sciences

    Cancer immunotherapy turns the body’s own immune system against tumours.[1] This crash course runs from how immune cells recognise cancer to the trials and approvals that define the field in October 2026. Choose a reading level in each section. Nothing here is medical advice: it describes evidence and regulatory status only.

    Why it matters

    Your immune system can spot and kill abnormal cells, but cancers find ways to hide or to switch immune cells off.[6] Immunotherapy tries to undo those tricks. The idea moved into routine care in 2011, when the FDA approved ipilimumab, the first drug that releases a “brake” on immune cells.[2] Today it is big business: Merck’s checkpoint drug Keytruda sold $31.7 billion in 2025.[7]

    Tumours evade immunity by reducing their visibility, expressing inhibitory ligands and remodelling the surrounding stroma.[6] Blocking inhibitory checkpoints such as CTLA-4 and PD-1 was the first approach to work at scale, beginning with ipilimumab in 2011.[2][8] Commercially, pembrolizumab alone generated $31.7 billion in 2025 sales.[7] Yet a 2019 analysis estimated that only about 12.5% of US patients would respond to checkpoint inhibitors, against 43.6% eligible.[9] Closing that gap drives most current research.

    The map of the field

    NCI sorts immunotherapy into a few families: checkpoint inhibitors, T-cell transfer therapy, lab-made antibodies, treatment vaccines and immune “boosters”.[3]

    The five NCI categories map onto distinct engineering problems.[3] Checkpoint blockade relieves inhibition of existing T cells.[10] Adoptive cell transfer (CAR-T, TIL, TCR-T) supplies T cells expanded or engineered ex vivo.[11] T-cell engagers such as tarlatamab (DLL3 x CD3) redirect T cells to a tumour surface antigen, while immune bispecifics such as ivonescimab combine PD-1 blockade with VEGF inhibition.[12][16] Neoantigen vaccines aim to prime new tumour-specific T cells.[17] ADCs deliver cytotoxic payloads and increasingly sit in combination regimens with PD-1 inhibitors.[14][15]

    Key ideas to hold on to

    Checkpoints protect healthy tissue, so releasing them can cause inflammation in organs such as the lungs, colon or thyroid.[18][19] Engineered cell therapies can trigger cytokine release syndrome, a surge of high fever and low blood pressure.[20] Blood cancers have been easier targets than solid tumours.[21]

    Immune-related adverse events are on-mechanism: in one ipilimumab trial 64% of patients had one and 18% had grade 3 or higher.[22] T-cell-redirecting therapies share cytokine release syndrome and ICANS as class toxicities, reflected in boxed warnings.[20][23] For solid tumours, NCI lists antigen scarcity, an immunosuppressive microenvironment and heterogeneity as the main barriers.[21]

    Who the main players are

    Merck’s pembrolizumab is the commercial anchor of checkpoint therapy, and Merck co-develops the personalised mRNA therapy intismeran autogene with Moderna.[7][13] BioNTech and Genentech run the rival autogene cevumeran programme.[24] Akeso reports the main trials of the PD-1 x VEGF bispecific ivonescimab, Summit Therapeutics has filed it for US approval, and BioNTech partnered its own PD-L1 x VEGF-A bispecific with Bristol Myers Squibb in 2025.[16][25][26] CARsgen’s satri-cel became the first solid-tumour CAR-T approval, in China.[5] Regulators shape the field too: the FDA added a boxed warning for secondary T-cell cancers after CAR-T in 2024, then removed CAR-T REMS programmes in 2025 to ease access.[27][28]

    Where the frontier is (October 2026)

    In August 2026 a personalised mRNA vaccine added to Keytruda beat Keytruda alone in a large melanoma trial, though full results are not yet published.[4][29] Weeks later, a similar vaccine’s colon cancer trial was stopped.[24] A new type of drug that blocks PD-1 and VEGF together beat Keytruda on survival in a lung cancer trial.[16] Scientists are also testing ways to make CAR-T cells inside the body with a single infusion.[30]

    Four threads define the frontier. First, neoantigen vaccines: INTerpath-001 (n=1,137) met RFS and DMFS endpoints, while BioNTech ended a colorectal monotherapy trial on an overall-survival imbalance.[4][24] Second, PD-(L)1 x VEGF bispecifics: HARMONi-2 reported an OS hazard ratio of 0.73 against pembrolizumab, and an FDA decision on ivonescimab is due by 14 November 2026.[16][25] Third, in vivo CAR-T: early myeloma data show deep responses alongside significant toxicity.[31][32] Fourth, solid-tumour cell therapy: satri-cel improved PFS in a randomised trial, at the cost of grade 3 or higher adverse events in 99% of patients.[33][34] The checkpoint story is also moving earlier in treatment, such as the October 2026 FDA approval of adjuvant atezolizumab in stage III dMMR colon cancer.[35]

    How to use this course

    Read the three fundamentals first, then the technology pages, then the solid-tumour debate. The tracker logs dated milestones.

    Questions readers ask

    What is cancer immunotherapy?

    It is a type of cancer treatment that helps the immune system fight cancer. NCI groups it into checkpoint inhibitors, T-cell transfer therapy, monoclonal antibodies, treatment vaccines and immune system modulators.[1][3]

    Does immunotherapy work for most patients?

    Not yet. A 2019 estimate found that about 43.6% of US cancer patients were eligible for checkpoint inhibitors in 2018, but only about 12.5% were expected to respond.[9]

    Is there an approved personalised mRNA cancer vaccine?

    Not as of October 2026. Merck and Moderna announced in August 2026 that their personalised mRNA therapy met its phase 3 endpoints in resected melanoma and said they would engage regulators on filings.[4][29]

    Has CAR-T been approved for any solid tumour?

    Yes, in China. In June 2026 China's NMPA approved satri-cel for claudin-18.2-positive gastric cancer, described as the first CAR-T approval for a solid tumour.[5]

    Sources

    Each numbered claim is a statement we checked against the sources listed with it. Status shows how well established it is.

    1. [1]

      The US National Cancer Institute defines immunotherapy as a type of cancer treatment that helps the immune system fight cancer. confirmedas of 2026-10-10

    2. [2]

      Ipilimumab (Yervoy), which blocks CTLA-4, became the first immune checkpoint inhibitor approved by the FDA, in 2011, for unresectable or metastatic melanoma. confirmedas of 2026-10-10

    3. [3]

      NCI lists the main types of cancer immunotherapy as immune checkpoint inhibitors, T-cell transfer therapy, monoclonal antibodies, treatment vaccines and immune system modulators. confirmedas of 2026-10-10

    4. [4]

      Merck and Moderna announced on 19 August 2026 that the 1,137-patient phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda in resected stage IIB-IV melanoma met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival versus Keytruda alone. confirmedas of 2026-08-19

    5. [5]

      In June 2026 China's NMPA approved CARsgen's satri-cel for claudin-18.2-positive, HER2-negative advanced gastric or gastro-oesophageal junction cancer, described as the first CAR T-cell therapy approved for a solid tumour. confirmedas of 2026-09-01

    6. [6]

      According to NCI, cancer cells can escape the immune system through genetic changes that make them less visible, surface proteins that switch off immune cells, and changes to the normal cells around the tumour. confirmedas of 2026-10-10

    7. [7]

      Merck reported 2025 worldwide sales of $31.7 billion for its PD-1 inhibitor Keytruda (pembrolizumab), including the subcutaneous Keytruda Qlex. confirmedas of 2026-02-03

    8. [8]

      The CTLA-4 pathway acts mainly at the level of lymph nodes during initial T-cell activation, while the PD-1 pathway acts mainly in tissues, where its ligands PD-L1 and PD-L2 are expressed in the tumour microenvironment. confirmedas of 2026-10-10

    9. [9]

      A 2019 study estimated that 43.6% of US patients with cancer were eligible for checkpoint inhibitors in 2018 but only about 12.5% would respond to them. confirmedas of 2019-05-03

    10. [10]

      Some tumours dampen T-cell responses by producing large amounts of the checkpoint protein PD-L1; checkpoint inhibitors block this binding so T cells can attack the cancer. confirmedas of 2026-10-10

    11. [11]

      NCI describes two main types of T-cell transfer therapy: tumour-infiltrating lymphocyte (TIL) therapy and CAR T-cell therapy. confirmedas of 2026-10-10

    12. [12]

      On 16 May 2024 the FDA granted accelerated approval to tarlatamab (Imdelltra), a DLL3 x CD3 bispecific T-cell engager, for extensive-stage small cell lung cancer after platinum chemotherapy; 40% of 99 patients responded. confirmedas of 2024-05-16

    13. [13]

      Intismeran autogene (mRNA-4157/V940), co-developed by Merck and Moderna, is an individualised mRNA therapy encoding up to 34 neoantigens chosen from each patient's tumour. confirmedas of 2026-08-19

    14. [14]

      Antibody-drug conjugates (ADCs) are targeted cancer drugs that link a monoclonal antibody to a highly toxic payload through a chemical linker. confirmedas of 2023-08-01

    15. [15]

      On 24 June 2026 the FDA approved the Trop-2-directed ADC sacituzumab govitecan with pembrolizumab for first-line PD-L1-positive metastatic triple-negative breast cancer; median progression-free survival was 11.2 versus 7.8 months in ASCENT-04. confirmedas of 2026-06-24

    16. [16]

      Akeso reported in September 2026 that its PD-1 x VEGF bispecific ivonescimab extended median overall survival to 30.8 months versus 22.6 months with pembrolizumab in first-line PD-L1-positive non-small cell lung cancer in the HARMONi-2 trial (hazard ratio 0.73). confirmedas of 2026-09-13

    17. [17]

      In a 16-patient pancreatic cancer study, the individualised mRNA vaccine autogene cevumeran induced new neoantigen-specific T cells in 8 patients, and these responders had longer recurrence-free survival than non-responders (median not reached vs 13.4 months). confirmedas of 2023-06-01

    18. [18]

      Immune checkpoints are a normal part of the immune system that stop immune responses from becoming so strong that they destroy healthy cells. confirmedas of 2026-10-10

    19. [19]

      Common side effects of checkpoint inhibitors include rash, diarrhoea and fatigue; rarer effects include widespread inflammation that can affect organs such as the lungs, colon, liver, heart and thyroid. confirmedas of 2026-10-10

    20. [20]

      The main acute CAR-T toxicities are cytokine release syndrome, which can cause dangerously high fevers and steep drops in blood pressure, and neurotoxicity (ICANS), with symptoms such as confusion and impaired speech. confirmedas of 2025-02-26

    21. [21]

      NCI identifies three obstacles for CAR T cells in solid tumours: few suitable surface antigens, an immunosuppressive tumour environment, and molecular variation between and within tumours. confirmedas of 2025-02-26

    22. [22]

      In an ipilimumab melanoma trial, 64% of patients had an immune-related adverse event of any grade and 18% had one of grade 3 or higher. confirmedas of 2026-10-10

    23. [23]

      T-cell engager labels such as tarlatamab's and teclistamab's carry boxed warnings for cytokine release syndrome and neurologic toxicity including ICANS. confirmedas of 2026-03-05

    24. [24]

      On 28 August 2026 BioNTech ended a phase 2 trial of autogene cevumeran monotherapy in resected colorectal cancer after its data monitoring board saw a numerical overall-survival imbalance between arms; the pancreatic cancer trial IMcode003 continues. confirmedas of 2026-08-28

    25. [25]

      The FDA accepted Summit Therapeutics' application for ivonescimab plus chemotherapy in EGFR-mutated non-squamous non-small cell lung cancer after TKI therapy, with a decision goal date of 14 November 2026. confirmedas of 2026-01-29

    26. [26]

      On 2 June 2025 BioNTech and Bristol Myers Squibb agreed to co-develop the PD-L1 x VEGF-A bispecific BNT327, with $1.5 billion upfront, $2.0 billion in anniversary payments through 2028 and up to $7.6 billion in milestones. confirmedas of 2025-06-02

    27. [27]

      In April 2024 the FDA required a boxed warning on six approved BCMA- or CD19-directed autologous CAR-T products for the risk of T-cell malignancies, and said patients should be monitored life-long for secondary cancers. confirmedas of 2024-04-18

    28. [28]

      In June 2025 the FDA removed the REMS safety programmes for approved autologous CAR-T therapies, cutting the recommended stay near a treatment centre from four weeks to two and the driving restriction from eight weeks to two. confirmedas of 2025-10-02

    29. [29]

      Merck and Moderna reported no new safety signals in INTerpath-001 and said they plan to present the data at a medical meeting and engage regulators on filings; full results had not been published as of the announcement. confirmedas of 2026-08-19

    30. [30]

      ESO-T01 is a lentiviral vector given as a single intravenous infusion that generates anti-BCMA CAR-T cells inside the body, without leukapheresis, ex vivo manufacturing or lymphodepleting chemotherapy. confirmedas of 2026-04-01

    31. [31]

      In a phase 1 study of ESO-T01 in five patients with relapsed or refractory multiple myeloma, four responded, including three stringent complete remissions. confirmedas of 2026-04-01

    32. [32]

      All five ESO-T01 patients had grade 3 or higher adverse events, four had cytokine release syndrome, one patient died from lesion-related spinal cord compression, and the trial was stopped early in 2025. confirmedas of 2026-04-01

    33. [33]

      In a randomised phase 2 trial of 156 patients with previously treated claudin-18.2-positive gastric or gastro-oesophageal junction cancer, the CAR-T therapy satri-cel extended median progression-free survival to 3.25 months versus 1.77 months with physician's choice (hazard ratio 0.37). confirmedas of 2025-06-01

    34. [34]

      In the satri-cel trial, grade 3 or higher adverse events occurred in 99% of satri-cel patients versus 63% of controls, and cytokine release syndrome in 95% of treated patients. confirmedas of 2026-06-22

    35. [35]

      On 8 October 2026 the FDA approved atezolizumab plus chemotherapy as adjuvant treatment for stage III mismatch repair deficient colon cancer, based on the ATOMIC trial (disease-free survival hazard ratio 0.50). confirmedas of 2026-10-08

    Revision history (1)
    1. Page created.

    Created Oct 10, 2026. Last reviewed by an editor on Oct 10, 2026. Next scheduled review: Jan 10, 2027.

    Cite this page

    "Cancer immunotherapy in 2026: a crash course." ContentLora, updated Oct 10, 2026. https://contentlora.com/explain/cancer-immunotherapy

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    Keep exploring

    ☰ Contents